|
Synonyms: compound 206 [WO2018228446A1] | PLB-1004 | PLB1004
andamertinib is an approved drug
Compound class:
Synthetic organic
Comment: The chemical structure for andamertinib was derived from WHO proposed INN list 132 (Feb 2025), in which it is listed as an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with antineoplastic potential. This generated a SMILES match via PubChem to a compound (206) that is claimed in patent WO2018228446A1 (Beijing Adamadle Biotechnology) [3]. Information provided in a clinical trials document (NCT06574347) indicates that andamertinib is a synonym for the clinical candidate PLB1004. PLB1004 is disclosed as an irreversible EGFR inhibitor that is designed to target EGFR with Ex20 insertion mutations [2] (this publication confirms the name to structure match). It is claimed that PLB1004 can cross the blood-brain barrier, meaning that it offers potential to reach metastatic lesions in the brain.
|
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| Andamertinib (as PLB1004) was progressed as a clinical candidate for the treatment of advanced or metastatic NSCLC. First approval was granted by China's NMPA in March 2026 [1], to treat Exon20 insertion mutated locally advanced or metastatic NSCLC. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT06574347 | Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC. | Phase 2 Interventional | Avistone Biotechnology Co., Ltd. | ||